Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueInventoryLiabilities and Shareholders EquityNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bioharvest Sciences (BHST) Receivables (2023 - 2025)

Bioharvest Sciences has reported Receivables over the past 3 years, most recently at $2.0 million for Q4 2025.

  • For Q4 2025, Receivables rose 77.51% year-over-year to $2.0 million; the TTM value through Dec 2025 reached $2.0 million, up 77.51%, while the annual FY2025 figure was $2.0 million, 77.51% up from the prior year.
  • Receivables was $2.0 million for Q4 2025 at Bioharvest Sciences, up from $1.4 million in the prior quarter.
  • Across five years, Receivables topped out at $2.0 million in Q4 2025 and bottomed at $808000.0 in Q4 2023.
  • The 3-year median for Receivables is $1.2 million (2024), against an average of $1.3 million.
  • The widest YoY moves for Receivables: up 78.34% in 2025, down 18.4% in 2025.
  • Over 3 years, Receivables stood at $808000.0 in 2023, then surged by 38.12% to $1.1 million in 2024, then soared by 77.51% to $2.0 million in 2025.
  • The last three reported values for Receivables were $2.0 million (Q4 2025), $1.4 million (Q3 2025), and $1.6 million (Q2 2025) per Business Quant data.